Drug Profile
Research programme: anti-CD44 variant monoclonal antibodies - MaimoniDex RA
Alternative Names: Anti-CD44 variant monoclonal antibodies research programme - Maimonidex RA; MD-101Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MaimoniDex RA
- Class Monoclonal antibodies
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Israel (Injection, Injection)
- 23 Sep 2005 MaimoniDex RA and Abmaxis have entered into an agreement to jointly develop a human monoclonal antibody for rheumatoid arthritis and other inflammatory diseases
- 15 Jul 2005 Anti-CD44 variant monoclonal antibodies are available for partnering